Could retatrutide ease your hunger and change your weight?
Your belt can loosen when your weight drops. Phase 2 means testing benefits and risks in larger groups. People receiving 12 mg lost an average 24.2% over 48 weeks. Your safety questions aren't all answered.
What can weight loss tell you, and what remains unknown?
Hunger can keep pulling you back toward the fridge. Researchers tested retatrutide for excess weight and type 2 diabetes. People lost weight, but some had troublesome side effects.
You can't yet get retatrutide as an approved medicine.
The FDA hadn't approved the drug, nor had other countries. Phase 3 means wider testing before possible approval. Those studies remained unfinished in 2026. Retatrutide copies three hormones. Hormones tell parts of your body what to do. GLP-1 and GIP come from your gut. Glucagon acts on your liver.
Hunger can ease while blood sugar drops. Your body may also burn more stored fuel.
Adults with obesity, meaning a great deal of excess body fat, joined a 48-week study. The largest tested amount resulted in an average loss of body weight of 24%. Earlier related drugs hadn't produced losses that large. Researchers compared the weight loss with weight-loss surgery.
You can't assume similar weight loss means similar risks.
People also felt sick and had bowel trouble. Their hearts beat faster when tested amounts were larger. Researchers don't know the risks over many years. What happens after people stop also needs checking.
Your strength and heartbeat matter alongside your weight.
Retatrutide effects covers people's experiences alongside the measured study harms. Some people tried research products outside those studies. Trials with comparison groups haven't confirmed those personal reports.
Their reports can't tell you what will happen to your health.
What does retatrutide do to hunger, sugar and weight?
Your hunger and blood sugar affect how your body uses food. Eli Lilly made retatrutide, also called LY3437943, in a lab. Researchers joined protein parts to make the drug. The joined parts let retatrutide act like three hormones [1].
Retatrutide isn't a hormone your body makes naturally.
GLP-1 can ease hunger and bring out insulin after meals. GIP helps release more insulin and changes how fat is used. Insulin helps your body use sugar from your blood. Glucagon helps your liver burn stored fat for fuel.
Tirzepatide copies the gut hormones but lacks that added glucagon effect.
How does retatrutide work explains those body changes. Phase 1 means the first checks in people. Phase 2 tests benefits and risks in larger groups. The Phase 2 weight study followed 338 adults in a 48-week study. Researchers used BMI, a score comparing weight with height. You'll need both height and weight to understand that score. The score had to reach 30, the study's cutoff for obesity.
That score isn't a weight or a waist measurement.
A taller person can weigh more at the same score. Your height matters when judging how the group compares with you. With 12 mg, people lost an average 24.2% of their weight. Placebo shots contained no drug; that group lost 2.1% [1].
Those percentages describe each group's average, not every person's loss.
Another Phase 2 test concerned adults who had type 2 diabetes. Their average loss reached 16.94% after 36 weeks with 12 mg. Their longer-term blood sugar test also improved. Sugar-test scores barely moved among people given drug-free shots [2]. Researchers followed those groups for a 36-week study.
You can't judge years of use from these months.
A 2024 Cell review discussed losses reaching about 20-30% [10]. The authors gave a range, rather than one study's average. The authors compared those losses with results from weight-loss surgery. You'll still need your doctor to assess each treatment's risks.
What were the retatrutide results in Phase 2?
A smaller waist was among the changes measured in people. Phase 2 tested people without diabetes in a 48-week study. The largest tested amount resulted in an average loss of body weight of 24.2%. Waists shrank by nearly 20 cm, about a hand's length. People receiving 1 mg lost an average 8.7% [1].
You can picture the waist change around a trouser belt.
The type 2 diabetes study was a 36-week test. People lost an average 16.94% of their weight; sugar control improved [2]. Another Phase 2 study checked fatty liver in a 48-week test. Fatty liver means too much fat inside the liver.
You won't always feel excess fat collecting inside your liver.
With 12 mg, liver fat dropped by 82.4% at 24 weeks. Scans showed normal liver fat in 86% of that group [5]. Normal meant liver fat measured below 5%.
A lower scan result doesn't settle lasting liver health.
An early test called Phase 1b studied people with type 2 diabetes. The letter marks part of that early testing stage. The blood still contained roughly half the retatrutide 6 days later. That's why study staff could consider shots each week. The largest studied amount produced more loss than placebo over 12 weeks [4].
That compares the weight lost by the two groups.
A 2025 Biomolecules review discussed weight losses reaching about 24% [6]. The authors saw a marked gain over earlier similar drugs. Larger Phase 3 studies hadn't finished by mid-2026. The TRIUMPH studies check weight, diabetes, heart and kidney health.
You couldn't yet read published Phase 3 results.
A separate test compares retatrutide directly with tirzepatide. Until results arrive, your comparison remains incomplete.
Is retatrutide FDA approved for patients?
Retatrutide still lacked FDA approval as of 2026. No other drug authority had approved the drug either. Eli Lilly's Phase 3 TRIUMPH studies were still running [6]. You can't be prescribed retatrutide as an approved medicine.
Your pharmacy can't supply an approved prescription form.
Despite the name, you can't order medicine from these pages. Research-labelled products don't undergo the checks required for approved medicines. You can't be sure those vials contain retatrutide. You also can't be sure the liquid is germ-free. The effects page's first caution, number 1, covers those vial concerns.
A research label doesn't protect you from a contaminated shot.
Retatrutide availability: Phase 3 studies still need to finish. Eli Lilly hasn't filed an application for drug approval. When will retatrutide be available? Good Phase 3 results would still need FDA review.
You can't put an announced approval date on your calendar.
The years 2027-2028 were only a forecast, without a named source. The forecast assumed successful tests and an approval application. The company hasn't promised those years. You can't plan your treatment around an unattributed forecast.
Retatrutide vs tirzepatide: which findings can you compare?
You may know tirzepatide as a diabetes or weight-loss medicine. Tirzepatide copies GIP and GLP-1, hormones involved in sugar and hunger. Retatrutide adds glucagon's effect on burning stored fuel. Researchers think that added effect helps explain greater weight loss [1][10].
That explanation can't choose the right medicine for your health.
Retatrutide's Phase 2 groups lost an average 24.2% of their weight. Tirzepatide's SURMOUNT-1 study reported weight loss around 20% at its largest amounts. Different people took part in these studies of GLP-1 drugs.
You can't read their averages as a direct contest.
No Phase 2 study had tested one drug against the other. TRIUMPH-4 includes a direct comparison, but results weren't published. A 2024 review compared seven drugs with GLP-1 effects [8]. Retatrutide ranked among those with the largest weight losses.
Your health involves more than the highest weight-loss rank.
Tirzepatide has approval; retatrutide remains in testing. Your doctor needs to judge the risks for you. Different people can respond differently to the same drug. Retatrutide research explains the added glucagon effect. Your doctor would also need the safety results.